

Table 10. Candidate genes in our dataset encoding for targets of existing pharmacological agents

| Accession Number | Symbol – Description   | Brain Region (Drug-Category) Fold Change          | No. of lines of evidence | Family                     | Drug  |
|------------------|--|---|--------------------------|----------------------------|---|
| U60150           | VAMP2 - vesicle-associated membrane protein 2 (synaptobrevin 2)                              | AMY (VPA-III) 0.71/ 0.5<br>CP (VPA-IV) 1.74/ 6.06 | 4/6                      |                            | botulism toxin  |
| J04192           | CHRM1 - cholinergic receptor, muscarinic 1   | CP (VPA-IV) 1.52/ 3.03                            | 3/6                      | Ion channel                | ipratropium, olanzapine, tolterodine                                      |
| AJ238309         | DAT1 – (SLC6A3) - solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 | VT (METH-IV) 1.41/ 1.74                           | 3/6                      | transporter                | amphetamine, modafinil, sibutramine, venlafaxine                          |
| U32329           | EDNRB - endothelin receptor type B   | CP (METH-III) 1.52/ 1.41                          | 2/6                      | G-protein coupled receptor | bosentan  |
| U14420           | GABRB3 - gamma-aminobutyric acid (GABA) A receptor, beta 3                                   | CP (VPA-IV) 1.41/ 14.9                            | 2/6                      | Ion channel                | lorazepam, olanzapine, sevoflurane, zaleplon, zolpidem                    |
| M62374           | GABRG2 - gamma-aminobutyric acid (GABA) A receptor, gamma 2                                  | CP (VPA-IV) 1.23/ 1.52                            | 2/6                      | Ion channel                | lorazepam, olanzapine, sevoflurane, zaleplon, zolpidem                    |
| M63685           | 5HTR2C - 5-hydroxytryptamine (serotonin) receptor 2C   | CP (METH-IV) 1.23/ 10.56                          | 2/6                      | G-protein coupled receptor | mirtazapine, nefazodone, olanzapine, quetiapine, risperidone, ziprasidone |

## Need to cite Ingenuity – Ingenuity Pathway Analysis

### From their web-site

#### Guidelines for Citing Use of Ingenuity Pathways Analysis

This document describes the policy and guidelines for publication of research results obtained using Ingenuity Pathways Analysis. Users are required to cite Paragraph A - Descriptions of Ingenuity Pathways Analysis, in their methods and materials sections. In addition, users should refer to Paragraphs B and C for guidelines to describe Ingenuity Pathways Analysis generated biological networks and functions, respectively.

#### Paragraph A - Descriptions of Ingenuity Pathways Analysis

"This data is generated through the use of Ingenuity Pathways Analysis, a web-delivered application that enables biologists to discover, visualize and explore therapeutically relevant networks significant to their experimental results, such as gene expression array data sets. For a detailed description of Ingenuity Pathways Analysis, visit [www.ingenuity.com](http://www.ingenuity.com)."